CO-OPTIV-SECURIT
10.6.2019 15:07:06 CEST | Business Wire | Press release
Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has been recognized by Forrester Research as a Strong Performer in The Forrester WaveTM : Global Cybersecurity Consulting Providers, Q2 2019. The report identifies Optiv as having received the highest possible score for six criteria:
- Delivery and engagement innovation
- IP and asset-based consulting
- Technical consulting and assessment capabilities
- Cybersecurity focus
- Go-to-market strategy
- Partnership ecosystems
“Optiv’s approach to cybersecurity is aligned to new business models and centered on driving client-focused outcomes. It is designed to optimize and rationalize existing cybersecurity programs, build new integrated, end to end cybersecurity programs, and help clients transform how they are consuming and applying cybersecurity,” said Bryan Wiese, division vice president, global advisory services for Optiv.
“We believe that receiving this designation from Forrester as a Strong Performer affirms our approach to consulting for global enterprises,” continued Wiese. “Historically, the fear of external threats and vulnerabilities has often guided clients’ security initiatives. That fear has sometimes led to tactical investment, too much of a focus on technology, and siloed problem solving. At Optiv we work with clients to manage their security programs from the ‘inside-out,’ starting with risk mitigation and building from there with customized strategy, focused process definition, technology rationalization and operations optimization, ongoing measurement and communication. Our approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change by providing new consumption and outcome-based consulting services and cybersecurity solutions. Our goal is help clients strike the right balance between risk mitigation, business alignment, and cost.”
Optiv’s full suite of advisory services can be consumed alone or combined with Optiv’s integration or managed services, or Cyber-as-a-Service (CaaSTM ) platform to harden security fundamentals across six main domains:
- Risk Management and Transformation – Optiv enables clients to address risk and regulatory changes with an inside-out strategy that begins with business needs and applies strategy, technology and processes to effectively manage risk and enable cyber resilience.
- Cyber Operations – Optiv helps clients strike the right balance of people, process, technologies and delivery methods in order to elevate threat preparedness while aligning business goals and operational resilience and producing measurable outcomes at reduced operational costs.
- Cyber Digital Transformation – Optiv aligns client business needs with a security-by-design approach that employs big data analytics, IoT, cloud, orchestration and automation and additional technology innovations to connect agile processes and controls.
- Identity and Data Management – Optiv helps clients tackle identity and data sprawl and exposure with comprehensive, strategic identity and data management solutions. Enabling organizations to quickly and securely provide access to the right company assets on- and off-premise ensures trust and compliance in the business while also strengthening security by classifying, governing and protecting sensitive data.
- Threat Management – Proactively solving threat management requires a comprehensive program that includes tracking technological and regulatory changes, driving security into network design and software development lifecycles, continual threat modeling, testing and remediation, an understanding of the attack surface, and readiness exercises to practice muscle memory and robust response should an incident occur.
Please visit Optiv’s website to learn more about Optiv’s cybersecurity consulting services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005093/en/
Contact:
Brett Ater (913) 304-7683 brett.ater@optiv.com or Jason Cook (816) 701-3374 jason.cook@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
